Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through November 5, 2021).
“HIV infection continues to threaten the health of women worldwide,” said Dr. Myron Cohen, HPTN co-principal investigator, and director of the Institute for Global Health and Infectious Diseases at the UNC-Chapel Hill. “Empowering women with safe and effective PrEP options is critical to reducing HIV as a global health threat.”